| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| AI Biotechnology LLC | 19.9% | $20.6M | 14.3M | AI Biotechnology LLC | 21 May 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 0% | $8.32M | -$888K | 6.35M | -9.64% | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2025 |
| JPMORGAN CHASE & CO | 7.5% | $5.65M | 4.67M | JPMORGAN CHASE & CO. | 30 Jun 2025 | |||
| GREAT POINT PARTNERS LLC | 5.87% | +15% | $16.5M | $2.8M | 3.82M | +20.4% | Great Point Partners, LLC | 30 Sep 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 4.9% | $4.63M | 3.22M | RA Capital Management, L.P. | 31 Dec 2024 | |||
| PFIZER INC | 4.6% | $4.28M | 2.97M | Pfizer Inc. 13-5315170 | 31 Dec 2024 | |||
| ADAR1 Capital Management, LLC | 3.18% | $2.99M | 2.08M | ADAR1 Capital Management, LLC | 31 Dec 2024 | |||
| Deep Track Capital, LP | 0.4% | -96.1% | $1.12M | -$18.9M | 259K | -94.4% | Deep Track Capital, LP | 30 Sep 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 41.1M | $178M | +$26.7M | $4.33 | 66 |
| 2025 Q2 | 35.3M | $37.1M | -$12.6M | $1.05 | 62 |
| 2025 Q1 | 45.7M | $59M | +$1.92M | $1.29 | 74 |
| 2024 Q4 | 42.9M | $107M | -$472K | $2.50 | 87 |
| 2024 Q3 | 37.2M | $151M | +$13.2M | $4.06 | 77 |
| 2024 Q2 | 32.8M | $115M | +$63.7M | $3.50 | 55 |
| 2024 Q1 | 14.8M | $37.6M | -$1.32M | $2.57 | 43 |
| 2023 Q4 | 15.1M | $70.7M | +$3M | $4.67 | 43 |
| 2023 Q3 | 14.1M | $93.3M | +$8.35M | $6.60 | 41 |
| 2023 Q2 | 12.8M | $105M | +$105M | $8.20 | 38 |
| 2023 Q1 | 25.7K | $24.7K | +$24.7K | $10.00 | 3 |